skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Base de dados/Biblioteca: Wiley-Blackwell Open Access Collection remover tipo de recurso: Web Resources remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
Material Type:
Web Resource 		Adicionar ao Meu Espaço

Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis

Reginster, Jean-Yves ; Bianic, F. ; Campbell, R ; Martin, M. ; Williams, S.A. ; Fitzpatrick, L.A.

John Wiley & Sons 2018

Texto completo disponível

Citações Citado por
2
A randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate
A randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate
Material Type:
Web Resource 		Adicionar ao Meu Espaço

A randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate

MILLER, P.D. ; PANNACCIULLI, N. ; BROWN, J.P. ; CZERWINSKI, E. ; NEDERGAARD, B.S. ; BOLOGNESE, M.A. ; MALOUF, J. ; BONE, H.G. ; Reginster, Jean-Yves ; SINGER, A. ; WANG, C. ; WAGMAN, R.B. ; CUMMINGS, S.R.

Wiley 2016

Texto completo disponível

Citações Citado por
3
The risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab
The risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab
Material Type:
Web Resource 		Adicionar ao Meu Espaço

The risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab

Kendler, D.L. ; Chines, A. ; Brandi, M.L. ; Papapoulos, S. ; Lewiecki, E.M. ; Reginster, Jean-Yves ; Roux, C. ; Munos Torres, M. ; Wang, A. ; Bone, H.G.

Wiley Liss, Inc 2016

Texto completo disponível

Citações Citado por
4
Chondroitin sulfate reduces pain and improves function in knee osteoarthritis significantly better than placebo, independently of the definition of responders
Chondroitin sulfate reduces pain and improves function in knee osteoarthritis significantly better than placebo, independently of the definition of responders
Material Type:
Web Resource 		Adicionar ao Meu Espaço

Chondroitin sulfate reduces pain and improves function in knee osteoarthritis significantly better than placebo, independently of the definition of responders

Reginster, Jean-Yves

Wiley Liss, Inc 2017

Texto completo disponível

Citações Citado por
5
Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment
Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment
Material Type:
Web Resource 		Adicionar ao Meu Espaço

Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment

FERRARI, S. ; LIBANATI, C. ; LIN, CJF ; ADAMI, S. ; BROWN, J.P. ; COSMAN, F. ; CZERWINSKI, E. ; de GREGORIO, L.H. ; MALOUF, J. ; Reginster, Jean-Yves ; DAIZADEH, N.S. ; WANG, A. ; WAGMAN, R.B. ; LEWIECKI, E.M.

Wiley 2015

Texto completo disponível

Citações Citado por
6
Can we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials
Can we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials
Material Type:
Web Resource 		Adicionar ao Meu Espaço

Can we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials

BROWN, J.P. ; DAKIN, P. ; HADJI, P. ; McCLUNG, M.R. ; MILLER, P.D. ; Reginster, Jean-Yves ; WAGMAN, R.B. ; WANG, A. ; McCLOSKEY, E.

Wiley 2015

Texto completo disponível

Citações Citado por
7
Pharmaceutical grade chondroitin sulfate improves knee osteoarthritis symptoms more than placebo and as much as celecoxib: results of the chondroitin vs celecoxib vs placebo trial (CONCEPT)
Pharmaceutical grade chondroitin sulfate improves knee osteoarthritis symptoms more than placebo and as much as celecoxib: results of the chondroitin vs celecoxib vs placebo trial (CONCEPT)
Material Type:
Web Resource 		Adicionar ao Meu Espaço

Pharmaceutical grade chondroitin sulfate improves knee osteoarthritis symptoms more than placebo and as much as celecoxib: results of the chondroitin vs celecoxib vs placebo trial (CONCEPT)

Reginster, Jean-Yves ; CONCEPT author's group

Wiley Liss, Inc 2016

Texto completo disponível

Citações Citado por
8
Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial
Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial
Material Type:
Web Resource 		Adicionar ao Meu Espaço

Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial

McClung, MR ; Langdahl, B ; Papapoulos, S ; Saag, KG ; Adami, S ; Bone, HG ; de Villiers, T ; Kiel, DP ; Kung, A ; Kumar, P ; Lim, SK ; Ling, X ; Lippuner, K ; Mautalen, C ; Nakamura, T ; Reginster, Jean-Yves ; Reid, IR ; Rodriguez-Portales, JA ; Roux, C ; Walliser, J ; Watts, NB ; Zanchetta, JR ; Zerbini, AF ; Rybak-Feiglin, A ; Cohn, D ; DaSilva, CA ; Massaad, R ; Santora, A ; Scott, BB ; Verbruggen, N ; Leung, A ; Lombardi, A

Wiley Liss, Inc 2014

Texto completo disponível

Citações Citado por
9
Association between lean mass and hip bone mineral density
Association between lean mass and hip bone mineral density
Material Type:
Web Resource 		Adicionar ao Meu Espaço

Association between lean mass and hip bone mineral density

Beaudart, Charlotte ; Reginster, Jean-Yves ; Slomian, Justine ; Buckinx, Fanny ; Bruyère, Olivier

Wiley Liss, Inc 2014

Texto completo disponível

Citações Citado por
10
Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment
Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment
Material Type:
Web Resource 		Adicionar ao Meu Espaço

Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment

Ferrari, S ; Libanati, C ; Lin, CJF ; Adami, S ; Brown, JP ; Cosman, F ; Czerwinski, E ; de Gregorio, LH ; Malouf, J ; Reginster, Jean-Yves ; Daizadeh, NS ; Wang, A ; Wagman, RB ; Lewiecki, EM ; Cummings, S

Wiley Liss, Inc 2014

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.